Status:
COMPLETED
Enterobacteriaceae Producing Extended-spectrum β-lactamases (ESBL) Decolonization Study
Lead Sponsor:
University Hospital, Geneva
Conditions:
Enterobacteriaceae Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Multidrug-resistant Enterobacteriaceae producing extended-spectrum β-lactamases (hereafter called ESBLs) have emerged as an important cause of bloodstream infection in hospitalized patients and urinar...
Eligibility Criteria
Inclusion
- Patients can be enrolled into the study provided that all of the following criteria are met:
- Microbiologically documented rectal carriage of ESBL-producing Enterobacteriaceae, without signs and symptoms of active infection with ESBL-producing Enterobacteriaceae at any body site
- Patient must give written informed consent to participate in the study. The informed consent can be given by the legal representative if necessary.
Exclusion
- Women who are pregnant or nursing
- Active infection
- Treatment with antimicrobial agents with activity against ESBL-producing Enterobacteriaceae
- Contraindication to the use of one of the study drugs (e.g. renal insufficiency with creatinine clearance \< 30 ml/min)
- Patient already enrolled in another study, or in the present study for a previous episode
- Psychiatric disorder or unable to understand or to follow the protocol directions
- Permanent indwelling urinary catheter that can not be changed
- Resistance of the ESBL-producing Enterobacteriaceae to one of the study drugs
- Known hypersensitivity to one of the study drugs
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00826670
Start Date
June 1 2009
End Date
August 1 2012
Last Update
August 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Geneva Universits Hospitals
Geneva, Switzerland, 1211